Epidemiological and clinical characteristics of inflammatory bowel diseases in Cairo, Egypt

doi:10.3748/wjg.v20.i3.814

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 3

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5946)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

440

WORD

236

HTML

3763

Figures (1-1)

160

Tables (1-6)

148

Sum=4747

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

636

Download

563

Sum=1199

Jan 21, 2014 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (33)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jan 21, 2014; 20(3): 814-821
Published online Jan 21, 2014. doi: 10.3748/wjg.v20.i3.814

Table 6 Type of treatment, relapses, histopathological and laboratory findings of Crohn's disease patients

CDAI (mean ± SD)	108.21 ± 53.84
CDAI (median/minimum/maximum)	103.33/38/259.5
Treatment used: (single drug or combinations) oral 5-ASA ± Metronidazole, ciprofloxacin, azathioprine, prednisone, infliximab,
surgical interference (yes/no)	7/15
Relapses (mean ± SD)	1.68 ± 2.21
Relapses (median/minimum/maximum)	1/0/8
Malignant transformation	None
Mean ESR 1^st hour (mean ± SD)	49.52 ± 30.98
CRP (positive/negative)	17/5
ANCA (positive/negative/not done)	6/16
ASCA (positive/negative)	4/18
Pathological findings included: cellular infiltrate, focal inflammation, microfisttulization, non caseating granulomas, cobblestoning, lymphoid hyperplasia
Pathology (diagnostic/suggestive/non conclusive)	7/8/7
Mean hemoglobin concentration, gm/dL (mean ± SD)	11.95 ± 2.14
Mean PLT count (mean ± SD)	296272.72 ± 146308.60
Mean TLC (mean ± SD)	7868.57 ± 2708.17

CDAI: Crohn’s disease activity index; ASA: Aminosalicylic acid; CRP: C-reactive protein; ANCA: Anti-neutrophil cytoplasmic antibodies; ASCA: Anti-Saccharomyces cerevisiae antibodies.

Citation: Esmat S, El Nady M, Elfekki M, Elsherif Y, Naga M. Epidemiological and clinical characteristics of inflammatory bowel diseases in Cairo, Egypt. World J Gastroenterol 2014; 20(3): 814-821
URL: https://www.wjgnet.com/1007-9327/full/v20/i3/814.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i3.814